{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:31:08Z","timestamp":1777498268920,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jocn.2014.05.028","type":"journal-article","created":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T03:01:10Z","timestamp":1408590070000},"page":"400-401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab"],"prefix":"10.1016","volume":"22","author":[{"given":"Lena-Alexandra","family":"Beume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick","family":"Dersch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Fuhrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Stich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Rauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf D.","family":"Niesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2014.05.028_b0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2014.05.028_b0010","unstructured":"Biogen Idec MedInfo. Available from https:\/\/medinfo.biogenidec.com\/medinfo\/download?doc=Letter+Bodies%2FNatalizumab+Safety+Update.pdf&type=pmldoc&Continue=Continue [accessed 10.05.13]."},{"key":"10.1016\/j.jocn.2014.05.028_b0015","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O\u2019Connor","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.05.028_b0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.22163","article-title":"Natalizumab dosage suspension: are we helping or hurting?","volume":"68","author":"West","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.05.028_b0025","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1177\/1352458508092810","article-title":"Early relapses after the first dose of natalizumab in active multiple sclerosis patients","volume":"14","author":"Centonze","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.05.028_b0030","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1177\/1352458509107011","article-title":"Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis","volume":"5","author":"Rinaldi","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.05.028_b0035","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/1352458510392263","article-title":"CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment","volume":"17","author":"Frisullo","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.05.028_b0040","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1371\/journal.pone.0003319","article-title":"Effects of natalizumab treatment on Foxp3+ T regulatory cells","volume":"3","author":"Stenner","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2014.05.028_b0055","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10875-011-9522-x","article-title":"Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism","volume":"31","author":"Ramos-Cejudo","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jocn.2014.05.028_b0050","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1172\/JCI11717","article-title":"Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis","volume":"107","author":"Theien","year":"2001","journal-title":"J Clin Invest"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586814003610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586814003610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T11:56:18Z","timestamp":1538308578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586814003610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0967586814003610"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2014.05.028","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2014.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}